The delivery and business
of cancer care are evolving
as fast as the disease itself

When it comes to precision medicine, it is common for health systems to focus on discrete points in time and tests for a patient or disease type.

But the bigger issue is operationalizing genomic testing at scale – identifying more patients and the right tests for them across the cancer care continuum.

Fragmented testing creates more administrative complexity and potential care deficiencies

An increase in diagnostic testing options allows more cancer patients to be evaluated for treatment—yet it may increase your administrative burden, put more pressure on the delivery of the highest quality cancer care, and adversely impact provider and patient satisfaction.

  • Health systems may be receiving different test results from multiple labs, using varied technologies
  • Managing this fragmented test data can be time-consuming and costly. Health systems leaders must weigh the complexity that comes with a diversity of tests, labs, and technologies with the efficiency of test standardization.